Low expression of Toll-like receptors in peripheral blood mononuclear cells of pediatric patients with acute lymphoblastic leukemia

Sánchez-Cuaxospa,María; Contreras-Ramos,Alejandra; Pérez-Figueroa,Erandi; Medina-Sansón,Aurora; Jiménez-Hernández,Elva; Torres-Nava,José R.; Rojas-Castillo,Emilio; Maldonado-Bernal,Carmen

doi:10.3892/ijo.2016.3569

Low expression of Toll-like receptors in peripheral blood mononuclear cells of pediatric patients with acute lymphoblastic leukemia

Authors:
- María Sánchez-Cuaxospa
- Alejandra Contreras-Ramos
- Erandi Pérez-Figueroa
- Aurora Medina-Sansón
- Elva Jiménez-Hernández
- José R. Torres-Nava
- Emilio Rojas-Castillo
- Carmen Maldonado-Bernal
View Affiliations

Affiliations: Immunology and Proteomic Research Laboratory, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico, Laboratory of Developmental Biology, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico, Department of Hematology and Oncology, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico, Oncology Service, Children's Hospital Moctezuma, Mexico City, Mexico, Institute of Biomedical Sciences, National Autonomous University of Mexico, Mexico City, Mexico
Published online on: June 7, 2016 https://doi.org/10.3892/ijo.2016.3569
Pages: 675-681

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is the second most common cause of death among children aged 1-14 years. Leukemia accounts for one-third of all childhood cancers, 78% of which is acute lymphoblastic leukemia (ALL). The development of cancer has been associated with malignant cells that express low levels of immunogenic molecules, which facilitates their escape from the antineoplastic immune response. It is thought that it may be possible to rescue the antineoplastic immune response through the activation of recognition receptors, such as Toll-like receptors (TLRs), which activate the innate immune system. TLRs are type I membrane glycoproteins expressed mainly in immune system cells such as monocytes, neutrophils, macrophages, dendritic cells, T, B and natural killer cells. The aim of the present study was to evaluate the expression of TLR1, TLR3, TLR4, TLR7 and TLR9 in peripheral blood mononuclear cells (PBMCs) in patients with ALL and prior to any treatment. PBMCs were obtained from 50 pediatric patients diagnosed with ALL and from 20 children attending the ophthalmology and orthopedics services. The mean fluorescence intensity was obtained by analysis of immunofluorescence. We found lower expression levels of TLR1, TLR3, TLR4, TLR7 and TLR9 in PBMCs from patients with ALL compared with those from control patients. We also observed that the PBMCs from patients with Pre-B and B ALL had lower TLR4 expression than controls and patients with Pro-B, Pre-B, B and T ALL had lower TLR7 expression than controls. The present study is the first to demonstrate reduced expression of TLRs in PBMCs from pediatric patients with ALL. This finding is of great relevance and may partly explain the reduction in the antineoplastic immune response in patients with ALL.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Stock W and Pui CH: Chapter 17. Acute lymphoblastic leukemia and lymphoblastic lymphoma. ASH-SAP. pp. 489–510. 2010
3	Hossain MJ, Xie L and Caywood EH: Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data. Cancer Epidemiol. 39:720–726. 2015. View Article : Google Scholar : PubMed/NCBI
4	Rakoff-Nahoum S and Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer. 9:57–63. 2009. View Article : Google Scholar
5	Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R and Jego G: Toll-like receptors: Lessons to learn from normal and malignant human B cells. Blood. 112:2205–2213. 2008. View Article : Google Scholar : PubMed/NCBI
6	Harsini S, Beigy M, Akhavan-Sabbagh M and Rezaei N: Toll-like receptors in lymphoid malignancies: Double-edged sword. Crit Rev Oncol Hematol. 89:262–283. 2014. View Article : Google Scholar
7	Fabricius D, Breckerbohm L, Vollmer A, Queudeville M, Eckhoff SM, Fulda S, Strauss G, Debatin KM, Jahrsdörfer B and Meyer LH: Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia. 25:1111–1121. 2011. View Article : Google Scholar : PubMed/NCBI
8	Månsson A, Adner M, Höckerfelt U and Cardell LO: A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology. 118:539–548. 2006.PubMed/NCBI
9	Marshak-Rothstein A: Toll-like receptors in systemic auto-immune disease. Nat Rev Immunol. 6:823–835. 2006. View Article : Google Scholar
10	Krieg AM and Vollmer J: Toll-like receptors 7, 8, and 9: Linking innate immunity to autoimmunity. Immunol Rev. 220:251–269. 2007. View Article : Google Scholar : PubMed/NCBI
11	Klonowska-Szymczyk A, Wolska A, Robak T, Cebula-Obrzut B, Smolewski P and Robak E: Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Mediators Inflamm. 2014:3814182014. View Article : Google Scholar : PubMed/NCBI
12	Green TL, Santos MF, Ejaeidi AA, Craft BS, Lewis RE and Cruse JM: Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol. 97:44–48. 2014. View Article : Google Scholar : PubMed/NCBI
13	Xu Y, Zhao Y, Huang H, Chen G, Wu X, Wang Y, Chang W, Zhu Z, Feng Y and Wu D: Expression and function of toll-like receptors in multiple myeloma patients: Toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol. 150:543–553. 2010. View Article : Google Scholar : PubMed/NCBI
14	Bernasconi NL, Onai N and Lanzavecchia A: A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 101:4500–4504. 2003. View Article : Google Scholar : PubMed/NCBI
15	Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C and Defrance T: TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol. 178:7779–7786. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gururajan M, Jacob J and Pulendran B: Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One. 2:e8632007. View Article : Google Scholar : PubMed/NCBI
17	Bourke E, Bosisio D, Golay J, Polentarutti N and Mantovani A: The toll-like receptor repertoire of human B lymphocytes: Inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 102:956–963. 2003. View Article : Google Scholar : PubMed/NCBI
18	Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V and Shi Y: Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma. 46:935–939. 2005. View Article : Google Scholar : PubMed/NCBI
19	Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, Endres S and Hartmann G: Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 168:4531–4537. 2002. View Article : Google Scholar : PubMed/NCBI
20	Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY and Wang RF: Toll-like receptor 8-mediated reversal of CD4⁺ regulatory T cell function. Science. 309:1380–1384. 2005. View Article : Google Scholar : PubMed/NCBI
21	Crellin NK, Garcia RV, Hadisfar O, Allan SE, Steiner TS and Levings MK: Human CD4⁺ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4⁺CD25⁺ T regulatory cells. J Immunol. 175:8051–8059. 2005. View Article : Google Scholar : PubMed/NCBI
22	Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M and Demengeot J: Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 197:403–411. 2003. View Article : Google Scholar : PubMed/NCBI
23	Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K and Reid GS: Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 132:452–458. 2006.PubMed/NCBI
24	Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, He L, Tomai MA, Miller RL, Booth J, et al: Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 20:286–295. 2006. View Article : Google Scholar
25	Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P and Caligaris-Cappio F: Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 144:507–516. 2009. View Article : Google Scholar
26	Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M and Schmitt M: Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion. 48:861–870. 2008. View Article : Google Scholar : PubMed/NCBI
27	Rybka J, Butrym A, Wróbel T, Jaźwiec B, Stefanko E, Dobrzyńska O, Poręba R and Kuliczkowski K: The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy. Leuk Res. 39:318–322. 2015. View Article : Google Scholar : PubMed/NCBI
28	Rozková D, Novotná L, Pytlík R, Hochová I, Kozák T, Bartůnková J and Spísek R: Toll-like receptors on B-CLL cells: Expression and functional consequences of their stimulation. Int J Cancer. 126:1132–1143. 2010. View Article : Google Scholar
29	Barcellini W, Imperiali FG, Zaninoni A, Reda G, Consonni D, Fattizzo B, Lonati S, Nobili L, Zanella A and Cortelezzi A: Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: Relationship with infections, autoimmunity and disease progression. Leuk Lymphoma. 55:1768–1773. 2014. View Article : Google Scholar
30	Webb RN, Cruse JM and Lewis RE: Decreased TLR4 gene expression in leukemic leukocyte populations. Exp Mol Pathol. 87:117–126. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S and Hartmann G: Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol. 174:4043–4050. 2005. View Article : Google Scholar : PubMed/NCBI
32	Reid GS, She K, Terrett L, Food MR, Trudeau JD and Schultz KR: CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood. 105:3641–3647. 2005. View Article : Google Scholar : PubMed/NCBI